encodes a seven trans-membrane (TM) G protein-coupled receptor that signals with high constitutive activity through Ga i Paulsen et al., 2005) . In this paper, the transforming potential of BILF1 is investigated in vitro in a foci formation assay using retrovirally transduced NIH3T3 cells, as well as in vivo by using nude mice. BILF1 revealed a substantial transforming potential that was dependent on constitutive signaling, as a signaling-deficient mutant completely lost its ability to transform cells in vitro, and an intermediately active triple-mutated receptor possessed an intermediate transforming potential. Furthermore, BILF1 expression induced vascular endothelial growth factor secretion in a constitutively active manner. In nude mice, BILF1 promoted tumor formation in 90% of cases, ORF74 (from Kaposi's sarcoma-associated herpes virus) in 100% of cases, whereas the signaling-deficient receptor resulted in tumor establishment in 40% of cases. These data suggest that BILF1, when expressed during EBV infection, could indeed be involved in the pathogenesis of EBV-associated diseases and malignancies. Furthermore, the correlation between receptor activity and the ability to mediate cell transformation in vitro and tumor formation in vivo supports the idea that inverse agonists for BILF1 could inhibit cell transformation and be relevant therapeutic candidates.
Introduction b-and g-herpes viruses encode seven trans-membrane (TM) receptors with structural and functional homologies to host receptors (Rosenkilde et al., 2008) . The viral 7TM receptors are divided into distinct subfamilies on the basis of sequence similarities (Paulsen et al., 2005; , clearly reflecting the evolutionary relatedness of the viruses. Several viral 7TM receptors possess chemokine-binding properties, as shown for the two best-studied receptors: US28 from human cytomegalovirus (Kledal et al., 1998) and ORF74 from Kaposi's sarcoma-associated herpes virus (KSHV) (Rosenkilde et al., 1999) . Thus, US28 binds a wide range of CC chemokines and CX3CL1 (Kledal et al., 1998) , whereas ORF74 binds a wide range of CXC chemokines (Geras-Raaka et al., 1998a, b; Rosenkilde et al., 1999) . Furthermore, both US28 and ORF74 are constitutively active (Arvanitakis et al., 1997; Waldhoer et al., 2002) . US28 signals through Ga q , Ga s and Ga 12/13 , further activating kinases and transcription factors, whereas ORF74 signals through Ga q , Ga s and Ga i , virtually activating the same downstream signal transduction pathways as US28 (Smit et al., 2002; Waldhoer et al., 2002; Streblow et al., 2003; McLean et al., 2004) . Furthermore, ORF74 and US28 stimulate the secretion of cytokines and growth factors, including vascular endothelial growth factor (VEGF) (Bais et al., 1998; Sodhi et al., 2000; Pati et al., 2001; Maussang et al., 2006) . Most viral 7TM receptors characterized to date are dispensable for viral replication in vitro but are important for viral success in vivo (Davis-Poynter et al., 1997; Vieira et al., 1998; Beisser et al., 1999) , presumably because of their function as immune-evasion molecules and/or their involvement in viral dissemination (Bodaghi et al., 1998; . It has been shown previously that ORF74 from KSHV is a potential oncogene because of its ability to transform cells in vitro (Bais et al., 1998; Pati et al., 2001 ) and induce Kaposi's sarcoma-like lesions in mice (Yang et al., 2000; Montaner et al., 2003) . Interestingly, US28 has also been shown to transform cells in vitro and form tumors in nude mice (Maussang et al., 2006) .
Recently, it was discovered that the Epstein-Barr virus (EBV) also encodes a 7TM receptor Paulsen et al., 2005) . Similar to US28 and ORF74, the EBV-encoded receptor, BILF1, is highly constitutively active. However, in contrast to US28 and ORF74, BILF1 signals selectively through Ga i in COS-7-and in HEK293 cells Paulsen et al., 2005) .
Furthermore, BILF1 also signals in a Ga i -dependent manner in the EBV-positive Burkitt's lymphoma cell line, HH514.c16, and in the EBV-positive lymphoblastoid B-cell line, JY . BILF1-specific mRNA is detected in various EBV-positive cell types during the immediate early and early phases of infection in vitro . BILF1 downregulates the phosphorylation of the double-stranded RNAdependent protein kinase (PKR) in COS-7 cells and in Burkitt's lymphoma B cells . Thus, BILF1 is a highly active receptor in both fibroblast and B-cell lines. In addition, BILF1 has been shown to interact and form heterodimers with host chemokine receptors (Vischer et al., 2008) . Interestingly, a direct immune regulatory function of BILF1 has been suggested as well (Zuo et al., 2009) . It was shown that BILF1 reduced the levels of MHC class I at the cell surface and inhibited CD8 þ T-cell recognition of endogenous target antigens. It was suggested that the underlying mechanism involved physical association of BILF1 with MHC class I molecules, as well as an increased turnover from the cell surface and enhanced degradation by lysosomal proteases (Zuo et al., 2009) .
7TM receptors have several highly conserved regions. One such region is the so-called 'DRY' (Asp-Arg-Tyr) motif located at the intracellular end of trans-membrane helix (TM)-III. The Arg (Arg 122 ) is the most conserved amino acid (96% among all class A rhodopsin-like receptors) (Mirzadegan et al., 2003) and is believed to be essential for G protein coupling. Interestingly, both BILF1 and ORF74 from KSHV have alternative 'DRY' motifs, whereas US28 contains the conserved motif. In ORF74, the 'DRY' motif sequence is 'VRY' (Val-ArgTyr) and in BILF1 the sequence is 'EKT' (Glu-LysThr) (Paulsen et al., 2005) . Alternative 'DRY' sequences have previously been shown to be associated with constitutive activity Maussang et al., 2006) . It is noteworthy that replacing the 'DRY' sequence in the human CXC chemokine receptor CXCR2 with the 'VRY' sequence from ORF74 resulted in a constitutively active receptor, capable of mediating cell transformation (Burger et al., 1999) .
KSHV and EBV are both associated with cancer development in humans. Thus, KSHV is associated with Kaposi's sarcoma, primary effusions lymphomas and multicentric Castlemans disease. EBV is associated with, for example, Hodgkin's and Burkitt's lymphoma, T/NK-cell lymphoma and nasopharyngeal carcinomas in immuno-competent humans, as well as with posttransplantation lymphomas (PTLDs), leiomyosarcomas and the nonmalignant syndrome oral hairy leukoplakia in immunocompromised humans (Kieff and Rickinson, 2007) . Because of the relatedness of KSHV and EBV and their role in cancer development and because of the functional similarities between the two 7TM receptors, ORF74 and BILF1, and the fact that ORF74 is a powerful oncogene (Arvanitakis et al., 1997; Yang et al., 2000) , the transforming potential of BILF1 was investigated, together with its role in cancer development.
In this study, we show that BILF1 mediates cell transformation in vitro and tumor formation in vivo. Furthermore, we show that the high constitutive activity of BILF1 is dependent on the alternative 'DRY' motif sequence (the 'EKT' sequence), and that the ability to induce cell transformation, stimulate VEGF secretion and promote tumor formation correlates with the level of constitutive receptor signaling through Ga i .
Results

BILF1 transforms cells
A foci formation assay using NIH3T3 cells was performed to investigate the transforming potential of BILF1. BILF1 (from human EBV), rhesus EBV BILF1 (rhBILF1), ORF74 and the empty expression vector (pb) were inserted into NIH3T3 cells by retroviral transduction. ORF74 was included as a positive control because of the previously shown oncogenic potential (Arvanitakis et al., 1997; Bais et al., 1998; Cesarman et al., 2000) . All three receptors induced foci formation with a higher frequency as compared with the spontaneous background formation in pb-transduced NIH3T3 cells (Figure 1a) . Thus, both BILF1 and rhBILF1 receptors are capable of inducing foci, suggesting an ability to transform cells, and thereby supporting the hypothesis that BILF1 is an oncogene.
BILF1 mutants are expressed identical to the wt receptor To investigate whether the BILF1-mediated constitutive activation of Ga i is necessary for BILF1-induced transformation, we altered the EKT sequence in TM-III of BILF1 in an attempt to generate a signalingsilenced receptor (Figure 2 ). The EKT [121] [122] [123] (Glu, Lys, Thr) sequence was changed to 'ERT' (Glu, Arg, Thr), 'EAT' (Glu, Ala, Thr) and 'DRY' (Asp, Arg, Tyr), respectively. All receptors were expressed as 50 kDa proteins in the inducible T-REx HEK293 system at comparable levels after induction with tetracycline, and no or only minute expression was observed without tetracycline (Figure 3a) . The surface expression level was determined using FACS, in which a clear and comparable shift in FITC intensity was observed in cells treated with tetracycline compared with nontreated cells (Figure 3b ). As the cells were not permeabilized, this reveals that all BILF1 constructs were expressed and present at the plasma membrane at comparable levels. Colocalization studies with a cellsurface-expressed human chemokine receptor, CXCR4, were conducted to verify that the receptor mutants were localized at the membrane as wt BILF1 (Figure 3c ). Briefly, T-REx HEK293 cells encoding either wt or a mutated BILF1 were transfected with a CXCR4-gfp fusion protein construct. All BILF1 receptor constructs colocalized to the plasma membrane with CXCR4-gfp (Figure 3c ), indicating that all receptors are indeed correctly folded and expressed regardless of sequence alterations.
Constitutive signaling through Ga i is dependent on the 'EKT' sequence Signaling through Ga i was determined by investigating receptor-mediated inhibition of forskolin-induced cAMP production. BILF1 significantly inhibited the forskolin-induced increase in cAMP ( Figure 4a ). As expected, the Ala substitution of Lys 121 (Lys 121 Ala, 'EAT') abolished this signaling, whereas the conservative substitution of Lys with Arg (Lys 121 Arg, 'ERT') signaled as wt BILF1 ('EKT') ( Figure 4b ). In contrast, the triple mutation (Glu Foci formation frequency correlates with the level of constitutive signaling To investigate whether the ability of BILF1 to transform cells and induce foci depended on constitutive signaling, foci formation assays were performed on NIH3T3 cells retrovirally transduced with different BILF1 receptor constructs. The 'ERT' mutation shows the same degree of foci formation as BILF1 and rhBILF1. In contrast, the 'DRY' mutation induces foci formation with a low frequency, although still above the background observed with the empty 3T3 pb vector (Figures 5a and c and 6a and b) . This corresponds to the observed intermediately impaired signaling (Figure 4b ). Furthermore, consistent with the abolished signaling (Figure 4b ), the 'EAT' receptor did not induce any foci in NIH3T3 cells (Figures 5a and c and 6a and b) . Hence, the ability of BILF1 to induce foci correlated well with the ability of BILF1 to signal constitutively through Ga i .
Increased cell growth and VEGF secretion are dependent on constitutive signaling To investigate the effect of receptor expression on cell growth, the growth of NIH3T3 pool clones was measured for 21days ( Figure 6c ). During the first 5 days of growth, no apparent differences were observed between the different clones expressing wt BILF1, wt ORF74 and 'EAT', as compared with cells containing the empty expression vector (Figure 6c ). However, after day 5, wt BILF1 and ORF74 continued to grow, corresponding to the ability of these receptors to inhibit the contact inhibition normally exerted by NIH3T3 cells and to promote cell transformation. In contrast, control cells and cells expressing the 'EAT' receptor exhibited a slowly decreasing cell number after day 5. Previously, both US28 and ORF74 have been shown to induce VEGF expression (Sodhi et al., 2000; Maussang et al., 2006) . To investigate the effect of receptor expression on VEGF secretion, conditioned media from NIH3T3 pool clones were assayed at indicated days over a 21-day period. Cells expressing Asterisks indicate significant differences (Po0.05) compared with NIH3T3 transduced with an empty expression vector (3T3 pb) analyzed using an unpaired one-tailed t-test (BILF1 P ¼ 0.0045; rhBILF1 P ¼ 0.0178; ORF74 P ¼ 0.007). (b) Fluorescence microscopy images of NIH3T3 cells transduced with BILF1, rhBILF1 and an empty expression vector. At 72 h after transfection, cells were fixed, permeabilized and stained with mouse anti-HA tag antibody for detection of HA-tagged receptor constructs, followed by staining with secondary Alexa Fluor 488-conjugated goat anti-mouse antibodies.
ORF74 secrete vast amounts of VEGF with an early onset ( Figure 6d ). Because of overconfluency, cells expressing ORF74 were unable to adhere properly to the wells and were lost after day 12. Cells expressing wt BILF1 and 'ERT' also secreted increased and similar levels of VEGF (Figures 6d and e). 'DRY'-expressing cells induced an intermediary amount of VEGF secretion, although with the same profile as wt BILF1 (Figures 6d and e) . This corresponds to DRY having an intermediary signaling and focus formation phenotype. 'EAT'-expressing cells showed no increase in VEGF secretion. This corresponds to the EAT growth, signaling and focus formation phenotype.
In vivo tumor formation depends on constitutive signaling through Ga i All mice (five out of five) injected with ORF74-expressing cells developed bilateral tumors (100%). Furthermore, all mice (four out of four) injected with wt BILF1-expressing cells developed tumors (three mice developed bilateral tumors and one mouse developed one unilateral tumor) (87.5%) (Figures 7a and b) . One mouse was killed before tumor development because of volvulus and was therefore excluded from the experiment. Of five mice injected with 'EAT' mutant-expressing cells, one developed bilateral tumors and two mice developed one unilateral tumor each (40%). None of the five mice injected with control cells showed any signs of tumor development. Thus, BILF1-mediated tumor formation in vivo is almost similar to that of ORF74. However, it was unexpected that 40% of the sites injected with 'EAT' mutant-expressing cells resulted in tumor formation. This result suggests that the constitutive activity through Ga i may not be solely responsible for tumor development.
To ensure that the NIH3T3 cells used in the in vivo experiment retained the same capability to support BILF1-mediated signaling as HEK293 cells, the signaling of BILF1, ORF74, 'EAT' and pb (control) in the NIH3T3 pool clones was measured (Figures 7c and d) . BILF1 inhibited the forskolin-induced increase in cAMP to a level similar to that of ORF74, whereas the 'EAT' construct did not reveal any signaling above the pb control (Figure 7c) . Thus, the BILF1 signaling pattern in NIH3T3 is very similar to the signaling pattern observed in HEK293 cells. Furthermore, the constitutive inhibition of the forskolininduced increase in cAMP by BILF1 and ORF74 was dependent on Ga i activation, as the activity of both receptors was inhibited by the addition of pertussis toxin (Figure 7d ).
Discussion
In this study, we have investigated the transforming potential of the EBV-encoded 7TM receptor BILF1. We show that BILF1 induces transformation of NIH3T3 cells and that its ability to transform cells is strongly, but not solely, correlated with the ability to signal constitutively through Ga i . Furthermore, we show that BILF1 induces VEGF secretion in vitro and tumor formation in vivo in nude mice, making BILF1 a bona fide oncogene.
As shown in Figure 1 , BILF1 transforms NIH3T3 cells almost as efficiently as ORF74. This result is somewhat remarkable because of the fact that BILF1 is restricted in its signaling compared with ORF74 and US28. To investigate whether Ga i was indeed necessary for BILF1-mediated cell transformation, a set of more or less silenced BILF1 mutants was constructed. In BILF1, the conserved 'DRY' (Asp, Arg, Tyr) motif is exchanged with an 'EKT' (Glu, Lys, Thr) motif. ) sequence were constructed. As expected, the different constructs revealed various degrees of impaired constitutive signaling, with the 'ERT' construct signaling similar to wt BILF1 in accordance with the earlier work on ORF74 (Ho et al., 2001) . The 'EAT' construct was completely silenced through Ga i , again in good accordance with earlier work on both ORF74 and US28 (Pleskoff et al., 2005; Maussang et al., 2006) . Finally, the reconstituted 'DRY' construct revealed an intermediate signaling phenotype (Figure 4) , despite maintained ability to downregulate MHC class I (Zuo et al., 2009) , indicating that the immune-modulating and the G protein-signaling/transforming properties of BILF1 are two distinct functions. Transformation studies comparing the wt BILF1 with the fully active 'ERT' mutant, the intermediately active 'DRY' mutant and the completely silenced 'EAT' mutant revealed that the ability of BILF1 to transform cells in vitro correlated with the ability of BILF1 to signal constitutively through Ga i . Thus, the activation of Ga i seems critical for the ability of BILF1 to mediate cell transformation.
Furthermore, it was shown that the level of signaling through Ga i correlated with the ability to induce VEGF secretion and the ability to sustain growth. Previously, VEGF secretion has been associated with the pathogenesis of both nasopharyngeal carcinoma (Murono et al.,
2001
; O'Neil et al., 2008) and non-Hodgkin's lymphomas (Paydas et al., 2008) and seemingly correlates with aggressive histology (Paydas et al., 2008) , recurrence (Krishna et al., 2006) and lower survival (Krishna et al., 2006) . Furthermore, BZLF1-deleted EBV-infected B cells, which are unable to undergo lytic replication, but can still immortalize primary B cells in vitro, are impaired in mediating angiogenesis and secrete less VEGF than wt infected B cells (Hong et al., 2005b) .The decreased secretion of VEGF from early passage LCLs, coupled with their known defect in establishing tumors in vivo (Hong et al., 2005a) , suggests that lytic induction of angiogenic factors such as VEGF may have a significant role in the pathogenesis of some EBVassociated malignancies and diseases (Hong et al., 2005b) .
The ability of BILF1 to induce tumors in nude mice was substantial, as 7 out of 8 inoculation sites developed tumors. Thus, the ability of BILF1 to form tumors in vivo is almost as strong as the ability of ORF74 from KSHV and very similar to that of US28 from cytomegalovirus (Maussang et al., 2006) . These data confirm that BILF1 is an oncogene, and suggest that BILF1 could be involved in the pathogenesis of EBVassociated malignancies. On the basis of our in vitro transformation experiments, it was unexpected that the 'EAT' mutant promoted tumorigenesis in vivo. Surprisingly, cells expressing the 'EAT' construct induced tumors in 40% of inoculation sites. Even though this is in contrast to the in vitro results, it is similar to that previously observed for US28 from cytomegalovirus, in which the Arg 129 Ala mutant in the 'DRY' motif, which is incompetent of both G protein signaling and cell transformation in vitro, also induced tumor formation in vivo in nude mice, although at a slower rate and to a lesser extent than wt US28 (Maussang et al., 2006) . Therefore, the BILF1 'EAT' (Lys 121 Ala) construct behaves in a manner similar to that of the US28 Arg 129 Ala construct. These data argue that BILF1 and US28 induce G protein-independent signaling, in addition to the distinctive G protein-, growth-promoting-and VEGFcomponent of the oncogenic process. Previously, it has been reported that 7TM receptors may signal independently of G proteins through, for example, GRKs, barrestin, Src and JAK/STAT (Rajagopal et al., 2005) . In the case of BILF1, it cannot be ruled out that it may induce tumor formation through interaction with other potentially transforming membrane proteins.
EBV-mediated cell transformation is involved in the development of cancers originating from blood, epithelial and smooth muscle cells. In the immunocompromised host, reactivation of EBV is associated with lymphomas (PTLDs) and leiomyosarcomas (Kieff and Rickinson, 2007) . Owing to a deficient immune system, lytic-infected cells are often detected in PTLD biopsies (Montone et al., 1996) . Furthermore, active EBV lytic replication is highly associated with the nonmalignant oral hairy leukoplakia syndrome (Walling et al., 2003) . In immunocompetent individuals, EBV is associated with the development of Hodgkin's disease (HD) and Burkitt's lymphoma (BL). HD is a B-cell lymphoma characterized by the presence of Hodgkin and ReedSternberg (HRS) cells surrounded by a large number of infiltrating nonmalignant cells (Kieff and Rickinson, 2007) . Lytic-infected cells are rarely found in EBVpositive HD (Pallesen et al., 1991) . BL is an EBVassociated malignancy most commonly located in the abdomen and jaw. It is endemic in central parts of Africa and has a high EBV association. EBV-positive BLs contain a small number of lytic-infected cells (Xue et al., 2002) .
Several latent genes can promote B-cell immortalization, and are necessary for EBV-mediated transformation (Kieff and Rickinson, 2007) . Owing to the strong association between latent gene products and EBVmediated B-cell immortalization in vitro, the focus on identifying genes responsible for cancer development has mainly been on these genes, in particular on the latent membrane protein 1 (LMP1) and EBVencoded nuclear antigens 2 (EBNA2) (Kieff and Rickinson, 2007) .
Interestingly, data are emerging that lytic gene products could also be involved in the development of EBV-associated cancers, as well as in nonmalignant syndromes, for example, oral hairy leukoplakia. Thus, recent data suggest that the continuously low levels of EBV lytic replication can contribute to initiate transformation and that a virus with deficient lytic replication is unable to promote EBV-mediated lymphoproliferative disease in SCID mice (Hong et al., 2005a) . Furthermore, it has been shown that the lytic gene BARF1 can induce tumor formation in SCID mice (Sheng et al., 2003) . These findings argue that lytic EBV gene products that most likely operate as transcription regulators or immune-response modulators may also contribute to cancer development, possibly by inducing or functioning as growth factors on uninfected or latently infected cells (Hong et al., 2005a) . Indeed, our in vivo data suggest that BILF1 promotes tumor formation by induction of growth and angiogenic factors.
Therefore, it is compelling to suggest that BILF1 and other 7TM receptors from, for example, KSHV, gHV68, AlHV1 and cytomegalovirus, all of which possess malignant properties in vitro and in several disease models, could be involved in the pathologies mediated by these viruses. It seems evident that g-herpes viruses and b-herpes viruses gain advantages in controlling the host's 7TM receptome either by interfering (a) with signals from specific ligands or (b) with the cell's endogenous 7TM receptor signaling system. Whether BILF1 is involved in the transformation process in the EBV-infected host is currently not known. However, the signaling activity of BILF1 and the marked cellular effects in vitro and in vivo resulting from BILF1 expression suggest an important role for this receptor during EBV infection and for the development of EBVassociated pathologies.
Materials and methods
Cell culture and regents
The generation of stable cell lines with inducible BILF1 expression has been described previously (Paulsen et al., 2005) . Expressions of the receptor constructs are induced by 0.5 mg/ml tetracycline (Invitrogen Q100-19). The T-REx-293 cell line and the HEK293 Phoenix packing cell line, kindly provided by Kristian Helin, BRIC, Copenhagen, Denmark, were cultured in DMEM (Lonza BE12-604F/U1) supplemented with 10% heat-inactivated fetal bovine serum (Sigma lot# 125K3397) and penicillin/streptomycin (Lonza DE17-602E). NIH3T3 cells were cultured in DMEM (Gibco 12800-116) with low NaHCO3 (1.5 g/l), 10% heat-inactivated calf serum (PAA cat# B15004) and penicillin/streptomycin. HEK293 cells were transfected using fugene-6 (Roche 1 814 433) according to the manufacturer's protocol. Receptor expression in NIH3T3 cells was obtained by retroviral transduction. All cells were cultured in 5% CO 2 at 37 1C.
Receptor constructs
Mutant receptors were generated using wild-type (wt) human BILF1 (BILF1) as template (Paulsen et al., 2005) . Briefly, BILF1 was tagged with a hem agglutinin (HA) tag using PCR and inserted into the pcDNA5/FRT/TO vector. Tyr (DRY)) were obtained by site-directed mutagenesis using Pfu polymerase (Stratagene 600159-81). After purification, the PCR products were cloned into pcDNA5/FRT/TO and pBabe puro, kindly provided by Kristian Helin, BRIC, Copenhagen, Denmark, by compatible end ligation using Quick ligase (NEB M2200L).
Retroviral transduction
Replication-deficient ecotropic retrovirus containing various receptor constructs was generated by transfecting the Phoenix cell line with the pBabe vector containing receptor genes. Supernatant viral particles were harvested 48 h after transfection by centrifuging at 2000 r.p.m. for 5 min and filtered through a 45 mm filter. The retroviral supernatants were aliquoted and stored at À80 1C before titration. The relative titer was determined on NIH3T3 cells as previously described (Greulich et al., 2005) .
Protein separation and western blot
For determination of size and to estimate the total expression levels of receptors in HEK293 cells, cells were lysed in 10 mM Tris-HCl, 1% SDS, followed by sonication. Equal amounts of protein were loaded on a 4-12% NuPage gel (Invitrogen NP0322) after boiling in 4 Â loading buffer (Invitrogen NP0008). Proteins were transferred to a PVDF membrane for 80 min at 150 mA, 30 V. The membrane was blocked in 5% SMP in PBS, incubated with mouse anti-HA antibodies (Biosite HA.11), washed in PBS, 0.05% tween 20, incubated with HRP-coupled goat anti-mouse antibodies (KPL 474-1806), washed and incubated with West Femto HRP substrate (Pierce 34095) for 5 min.
Receptor localization and surface level expression Receptor localization in HEK293 cells was investigated using confocal microscopy. The localization of all receptor mutants was compared with the localization of human CXCR4-gfp. Cells were grown in a CC2-treated Lab-Tek chamber slide (Nalge Nunc International 154917). One day after seeding, cells were transfected with CXCR4-gfp. At 24 h after transfection, the medium was changed and tetracycline was added to induce BILF1 expression. At 48 h after transfection, cells were fixed in 3.7% formaldehyde, permeabilized in PBS, 0.2% Triton Â 100 on ice, blocked in PBS, 1% BSA, 5% goat serum, washed in PBS, 1% BSA and stained with mouse anti-HA antibody (Biosite HA.11), washed and incubated with secondary Alexa Fluor 594-conjugated goat anti-mouse antibody (Molecular probes A11058). Cells were mounted with Fluoromount-G (Southern Biotechnology Associates 0100-01). Confocal fluorescence microscopy was performed on a Zeiss Axioplan 2 microscope using a 63 Â oil immersion objective. Surface expression levels were determined using fluorescence-activated cell sorting (FACS) analysis. Cells were transfected and induced as above. After harvesting using Versene, the cells were washed in FACS buffer (PBS, 0.5% BSA, 0.05% azide), blocked in 5% goat serum in FACS buffer, incubated with mouse anti-HA antibody (Biosite HA.11) for 1 h, washed and incubated with secondary Alexa Flour 488-conjugated goat anti-mouse antibodies (Molecular probe A11001). After immunostaining, cells were fixed in 3.7% formaldehyde, washed and analyzed on a BD Biosciences FACS DIVA.
cAMP assay HEK293 cells were seeded at 10 4 cells per well in 96-well plates and allowed to adhere for 24 h. After 24 h, receptor expression was induced by tetracycline and, 48 h after seeding, the adenylate cyclase was stimulated with forskolin (Sigma F3917)) at different concentrations for 15 min and the assay was performed according to the manufacturer's protocol (GE RPN225). Control samples were stimulated with DMSO diluted in media.
Focus formation assay Subconfluent NIH3T3 cells grown in a T25 flask were transduced with retrovirus carrying the individual receptor construct as described above. At 48 h after infection, the transduced cells were seeded in six-well plates (10 5 cells/well). The medium was changed every 3-4 days for 21 days. After 21 days, cells were fixed in 3.7% formaldehyde and stained with 0.1% crystal violet. After staining, plates were dried and foci were counted. To account for differences in viral transduction efficiency, the viral titer was estimated by measuring cell proliferation under puromycin selection. Briefly, 48 h after transduction, 10 5 cells per well were seeded in six-well plates in media containing puromycin. Cells were left for 72 h and proliferation was assayed using the WST-1 reagent (Roche). The number of foci was normalized to the Abs450 obtained from the proliferation assay multiplied by the dilution factor used for the initial infection (Figure 5b ).
Cell growth
Growth of NIH3T3 cell receptor pool clones was estimated using the WST-1 reagent (Roche). Briefly, 2.5 Â 10 4 cells per well were seeded in duplicate in six-well plates and allowed to grow for 21 days. Proliferation was estimated at the indicated time points by adding 200 ml WST-1 reagent to each well and incubating for 1 h at 37 1C. Color reaction was measured at Abs450. The NIH3T3 pool clones were generated by growing transduced cells under puromycin selection.
VEGF measurement VEGF was measured in conditioned media from NIH3T3 cells expressing wt BILF and receptor mutants during a focus formation assay using a quantikine, mouse VEGF ELISA kit, R&D Systems cat # MMV00 according to the manufacturer's protocol. Briefly, 10 5 cells per well were seeded in duplicate in six-well plates and VEGF was measured 24 h after media change on indicated days.
In vivo tumor formation Eight-week-old nude female BALB/c mice (Charles River Laboratories) were injected with NIH3T3 pool clones expressing either ORF74 (positive control), wt BILF1, the EAT mutant or pBabe puro empty vector (negative control) and monitored for 7 weeks for tumor formation. Each group contained five mice. Mice were sedated with FenDroMid before the injection of 1 Â 10 6 NIH3T3 cells suspended in 0.2 ml PBS into each flank. Tumor growth was monitored twice a week for 7 weeks. Animals were killed if the tumor exceeded more than 1 cm 3 . During the experiment, one mouse injected with wt BILF1 expressing NIH3T3s was killed because of volvulus. The experiment was approved by the Danish supervisory authority for animal testing.
